Unassociated Document

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: October 25, 2011
(Date of Earliest Event Reported)


LARREA BIOSCIENCES CORPORATION
(Exact Name of Registrant as Specified in its Charter)



Nevada	0-50281	68-0507505
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1628 Marshall, Houston, TX 77006		77006
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (832) 695-0096

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230 .425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 OTHER EVENTS

Larrea Biosciences Inc. announced on October 25, a Demand Note Extension with lenders for five years and the renaming of a Wholly Owned Subsidiary as Gordian Resources, Inc. a Delaware, Corporation Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(b) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	LARREA BIOSCIENCES CORP.

Date: October 25, 2011	By:	/s/ Peter P. Smetek, Jr.
		Name: Peter P. Smetek, Jr. Title: Chairman CEO

Larrea Biosciences, Inc.

1628 Marshall

Houston, Texas 77006-4122

832-695-0096 Fax 832-285-1307

www.LarreaRx.com

ps@larrearx.com

October 25, 2011

Larrea Biosciences Announces Loan Extension and Corporate Restructuring

Larrea Biosciences announces that it has extended it long term demand note of Two Million Fifty Five Thousand Dollars($2,055,509) with its lenders for five years until October 31, 2016. The lenders agreed to take stock in lieu of cash for interest payments due valuing that common stock at two cents a share and equaling nineteen million seventy-nine shares ($19,079,000) of common stock of Larrea Biosciences, which increases the shares outstanding to forty six million seventy-nine thousand four hundred thirty nine shares (46,079,439), giving the lenders effective control of seventy-one percent (71%) ofthe common stock of Larrea Biosciences. Fifty-one percent of the shares of Larrea Biosciences were originally pledged as collateral for the initial loans to Larrea in September of 2004, Larrea defaulted on this loan and subsequent loans in October of 2007, the lenders took stock in lieu of cash and extended the loan five years. The primary lender is Smetek and Associates, Inc. which controls a number of subsidiary companies which have lent Larrea Biosciences, Inc. funds since September, 2004. Smetek and Associates, controls another eight-million shares (8,000,000) of common stock for services rendered and is also owed three hundred and eight thousand two hundred and thirty dollars ($308,230.31) in short term loans, which have been advanced to Larrea Biosciences in order for it to remain viable. Eighty-eight per cent (88%) of the common stock is controlled by Smetek and Associates, Inc. and the lenders.

Larrea Biosciences has also re-named one of its subsidiary companies, Gordian Resources, Inc. a Delaware Corporation, of which it currently holds one hundred percent of the Common Stock. Gordian will act as managing general partner in the acquisition of Natural Resource Assets, primarily Oil and Gas onshore in the lower continental United States. It is the intention of Larrea Biosciences to spin off the common stock of Gordian, after it acquires adequate funding to make acquisitions as a working interest owner in a number of fields and prospects and it has begun negotiations with the current owners of those prospects.

Questions regarding this press release can be answered by calling Larrea Biosciences at:

832-695-0096

Or E-mailing

Peter Smetek at: ps@larrearx.com